Health
China Sinopharm’s Potential COVID-19 Vaccine Triggers Antibodies in Clinical Trials: Journal – The New York Times
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
The results were based on data from 320 healthy adults in Phase 1 and 2 trials.
The candidate triggered robust antibody responses in inoculated people, but it remained unknown if that was sufficient to prevent COVID-19 infection, re…
-
Noosa News21 hours agoFamily pleads for help after 17-year-old Pheobe Bishop disappears in Bundaberg before flight
-
Noosa News24 hours agoNo conviction recorded for teen behind attack on Peter Dutton’s office
-
Business22 hours agoASX 200 lifts on the RBA’s latest interest rate call
-
General14 hours agoTop chess player Magnus Carlsen forced into draw in historic game against over 134,000 people